Industry Newsclinical trialscmltern pharmaceuticalsbiopharma
Terns Pharmaceuticals Gains Analyst Support For TERN-701
6.1
Terns Pharmaceuticals saw analysts reaffirm bullish ratings after Phase 1 TERN-701 data; Truist reiterated a Buy on Jan. 8 with a $56 target and Mizuho kept an Outperform and $54 target. The trial showed a 64% major molecular response rate at 24 weeks, and CEO Amy Burroughs aims pivotal trials by the end of 2026; shares rose over 300% in the past three months.
Key Points
- 1Reports 64% major molecular response by 24 weeks in Phase 1 TERN-701 study
- 2Analysts reiterate Buy/Outperform with price targets $54–$56, reflecting clinical promise
- 3Investors view stock as high-growth; shares rose over 300% last three months
Scoring Rationale
Moderate market-moving analyst confirmation and robust Phase 1 data, limited by single-company scope and non-technical relevance.
Sources
Public references used for this report.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
Used by DS/ML engineers at top companies
250 free problems · No credit card
See all Health & Insurance problems
